Intellia Therapeutics, Inc.

Ownership Transactions Reported by 18 Insiders

Symbol
NTLA on Nasdaq
Location
40 Erie Street, Suite 130, Cambridge, Massachusetts

Insiders trading volume in the past year

Intellia Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
John M. Leonard President and CEO, Director $30.1 M -$566 K -1.85% Mar 1, 2024
David Lebwohl EVP, Chief Medical Officer $2.81 M -$172 K -5.77% Mar 1, 2024
Laura Sepp-Lorenzino EVP, Chief Scientific Officer $2.79 M -$229 K -7.59% Mar 1, 2024
James Basta EVP, General Counsel $2.69 M -$188 K -6.53% Mar 1, 2024
Derek Hicks EVP, Chief Business Officer $2.19 M -$114 K -4.96% Mar 1, 2024
Glenn Goddard EVP, Chief Financial Officer $2.11 M -$158 K -6.98% Mar 1, 2024
Eliana Clark EVP, Chief Technical Officer $1.64 M -$165 K -9.16% Jul 1, 2024
Fred E. Cohen Director $1.63 M Jun 12, 2024
Michael P. Dube VP, PAO and Interim PFO $1.23 M Jul 1, 2024
William Chase Director $881 K Jun 12, 2024
Georgia Keresty Director $788 K Jun 12, 2024
Muna Bhanji Director $651 K -$17.6 K -2.63% Jun 12, 2024
Jesse Goodman Director $642 K Jun 12, 2024
Brian Goff Director $508 K Jun 13, 2024
Frank Verwiel Director $449 K -$37.6 K -7.74% Jun 17, 2024
Caroline Dorsa Director $373 K Jun 14, 2022
John F. Crowley Director $344 K Jun 14, 2023
Jean Francois Formela Director $214 K Jun 14, 2022

Recent Insider Transactions by Companies or Individuals for Intellia Therapeutics, Inc.

Insider Class Transaction % Value $ Price $ Shares Shares Owned Date Ownership